市場調查報告書

全球擴大性心肌病治療市場:成長,趨勢,及預測

Dilated Cardiomyopathy Therapeutic Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921955
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
全球擴大性心肌病治療市場:成長,趨勢,及預測 Dilated Cardiomyopathy Therapeutic Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 112 Pages
簡介

本報告提供全球擴大性心肌病治療藥市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,藥物類別·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 心臟病盛行率的增加
    • 藥物與酒精濫用
  • 市場阻礙因素
    • 擴大性心肌病治療藥的副作用
  • 波特的五力分析

第5章 市場區隔

  • 各類藥物
    • 醛固酮拮抗劑
    • 血管收縮素轉化酵素(ACE)抑制劑
    • 血管收縮素II受體阻斷劑
    • Beta阻滯劑
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Zensun Shanghai Sci & Tech Co Ltd
    • Capricor Therapeutics, Inc.
    • Vericel Corporation
    • AstraZeneca plc.
    • Pfizer Inc.
    • t2cure GmbH
    • MyoKardia and Kasiak Research pvt.ltd.

第7章 市場機會及今後趨勢

目錄
Product Code: 67502

Market Overview

The dilated cardiomyopathy therapeutics market is anticipated to grow with a CAGR of nearly 3.6% during the forecast period. The major factors attributing to the growth of the dilated cardiomyopathy therapeutics market are increasing life expectancy and increasing prevalence of heart problems. Furthermore, the increasing number of people suffering from cardiac muscle infections, along with drug or alcohol abuse are also the factors that push the growth of the market.

According to the British Heart Foundation (BHF), 17,06,213 cases of cardiovascular diseases are diagnosed in the United Kingdom alone. As per the statistics, the incidence of cardiovascular diseases is increasing which is directly proportional to the market growth. Whereas the side effects of dilated cardiomyopathy therapeutics that cause serious discomfort to the patients are restraining the market.

Scope of the Report

According to the scope of the report dilated cardiomyopathy is a heart disorder that is caused due to the enlargement of the heart. The market is segmented by Drug Class and Geography.

Key Market Trends

Outstanding clinical results and satisfactory patient compliance of Drug Class makes it suitable for the treatment of Dilated Cardiomyopathy

  • Dilated cardiomyopathy is a disease where the ability of the heart to pump blood is decreased due to the enlargement of the left ventricle.
  • The driving factors of the segment are the excellent results of the therapy and the high prevalence of heart diseases. Due to the advancements in healthcare segment, the average life expectancy of an individual is increasing, which results in the rise in the geriatric population, who are more susceptible to heart diseases.
  • According to the World Health Organization (WHO), cardiovascular diseases is the number one cause of death globally, taking an anticipated 17.9 million lives each year.
  • Therefore as the prevalence of heart diseases increases the growth of the market increases too.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall dilated cardiomyopathy therapeutics market, throughout the forecast period. The growth is due to the rising incidence of cardiovascular diseases, well-established insurance policies and the availability of advanced healthcare infrastructure are the major factors. In the North America region, the United States holds the largest market share due to factors such as an increasing number of geriatric populations, along with a growing number of heart diseases in the country, which is anticipated to stimulate the demand in this region. According to the American College of Cardiology (2017), Cardiovascular disease accounts for 800,000 deaths in the United States. As the number of cardiovascular diseases increases the market for dilated cardiomyopathy rises.

Competitive Landscape

The dilated cardiomyopathy therapeutics market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc, AstraZeneca plc., Vericel Corporation, Pfizer inc., t2cure GmbH, MyoKardia, and Kasiak Research pvt.ltd.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing prevalence of heart problems
    • 4.2.2 Drugs and alcohol abuse
  • 4.3 Market Restraints
    • 4.3.1 The side effects of dilated cardiomyopathy therapeutics
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Aldosterone antagonists
    • 5.1.2 Angiotensin-converting enzyme (ACE) inhibitors
    • 5.1.3 Angiotensin II receptor blockers
    • 5.1.4 Beta-blockers
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Zensun Shanghai Sci & Tech Co Ltd
    • 6.1.2 Capricor Therapeutics, Inc.
    • 6.1.3 Vericel Corporation
    • 6.1.4 AstraZeneca plc.
    • 6.1.5 Pfizer Inc.
    • 6.1.6 t2cure GmbH
    • 6.1.7 MyoKardia and Kasiak Research pvt.ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS